Skip to main content
Professional Technical IVT

aromatase inhibitor

Pronunciation: uh-ROH-muh-tayss in-HIB-i-ter

A class of hormone therapy drugs that block estrogen production in postmenopausal women with hormone receptor-positive breast cancer.

Full Definition

Aromatase inhibitors (AIs) are medications that block the enzyme aromatase, which converts androgens to estrogens in postmenopausal women. By reducing estrogen levels, these drugs help prevent hormone receptor-positive breast cancer cells from receiving growth signals. Common aromatase inhibitors include anastrozole, letrozole, and exemestane. They are typically used as adjuvant therapy in postmenopausal women or in metastatic settings. Side effects may include bone loss, joint pain, and menopausal symptoms. AIs are generally more effective than tamoxifen in postmenopausal women.

Usage

Usage note: Specify generic name (anastrozole, letrozole, exemestane) when discussing specific agents.

In Context

  • "The patient was switched from tamoxifen to an aromatase inhibitor after becoming postmenopausal." — Treatment modification note
  • "Aromatase inhibitor therapy will continue for five years with annual bone density monitoring." — Follow-up care plan

Also known as

AI aromatase blocker

Contrasted with

selective estrogen receptor modulator

Don't confuse with

selective estrogen receptor modulator estrogen receptor antagonist

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON